➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
McKesson
Johnson and Johnson
Merck
Harvard Business School

Last Updated: April 18, 2021

DrugPatentWatch Database Preview

TRANYLCYPROMINE SULFATE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Tranylcypromine Sulfate patents expire, and what generic alternatives are available?

Tranylcypromine Sulfate is a drug marketed by Kinedexe and Par Pharm and is included in two NDAs.

The generic ingredient in TRANYLCYPROMINE SULFATE is tranylcypromine sulfate. There are six drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the tranylcypromine sulfate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tranylcypromine Sulfate

A generic version of TRANYLCYPROMINE SULFATE was approved as tranylcypromine sulfate by PAR PHARM on June 29th, 2006.

  Start Trial

Summary for TRANYLCYPROMINE SULFATE
US Patents:0
Applicants:2
NDAs:2
Suppliers / Packagers: 4
Formulation / Manufacturing:see details
What excipients (inactive ingredients) are in TRANYLCYPROMINE SULFATE?TRANYLCYPROMINE SULFATE excipients list
DailyMed Link:TRANYLCYPROMINE SULFATE at DailyMed
Drug patent expirations by year for TRANYLCYPROMINE SULFATE
Pharmacology for TRANYLCYPROMINE SULFATE
Medical Subject Heading (MeSH) Categories for TRANYLCYPROMINE SULFATE

US Patents and Regulatory Information for TRANYLCYPROMINE SULFATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kinedexe TRANYLCYPROMINE SULFATE tranylcypromine sulfate TABLET;ORAL 206856-001 Apr 17, 2018 AB RX No No   Start Trial   Start Trial   Start Trial
Par Pharm TRANYLCYPROMINE SULFATE tranylcypromine sulfate TABLET;ORAL 040640-001 Jun 29, 2006 AB RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Moodys
Baxter
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.